Noscapinoid-producing Microbes and Methods of Making and Using the Same
Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.
1 - 120 . (canceled)
121 . An engineered non-plant cell that produces a benzylisoquinoline alkaloid product that is along a metabolic pathway that converts canadine to a noscapinoid product;
wherein an amount of the benzylisoquinoline alkaloid product that is produced in the engineered non-plant cell is more than the amount of the benzylisoquinoline alkaloid product that is produced in the non-plant cell; and
wherein the engineered non-plant cell comprises one or more heterologous coding sequences encoding at least one enzyme involved in the metabolic pathway that converts canadine to a noscapinoid product.
122 . The engineered non-plant cell of claim 121 , wherein the engineered non-plant cell comprises heterologous coding sequences encoding more than one enzyme involved in the metabolic pathway that converts canadine to a noscapinoid product.
123 . The engineered non-plant cell of claim 122 , wherein the engineered non-plant cell comprises heterologous coding sequences encoding two distinct enzymes involved in the metabolic pathway that converts canadine to a noscapinoid product.
124 . The engineered non-plant cell of claim 121 , wherein the at least one enzyme is capable of converting a compound within the engineered non-plant cell into the benzylisoquinoline alkaloid product.
125 . The engineered non-plant cell of claim 121 , wherein the at least one enzyme involved in the metabolic pathway that converts canadine to a noscapinoid product is selected from the group consisting of tetrahydroprotoberberine-N-methyltransferase, 1-hydroxy-N-methylcanadine 13-hydroxylase, N-methylcanadine 14-hydroxylase, 4′-O-desmethyl-3-O-acetylpapaveroxine synthase, 1,13-dihydroxy-N-methylcanadine 13-O acetyltransferase, norcoclaurine 6-O-methyltransferase, narcotinehemiacetyl synthase, noscapine synthase, and narcotoline 4′-O-methylase I, and narcotoline 4′-O-methylase II.
126 . The engineered non-plant cell of claim 121 , wherein the benzylisoquinoline alkaloid product is a phthalideisoquinoline product selected from the group consisting of: a narcotolinehemiacetal, narcotinehemiacetal, narcotoline, and noscapine.
127 . The engineered non-plant cell of claim 121 , wherein the benzylisoquinoline alkaloid product is a protoberberine product selected from the group consisting of: a N-methylcanadine, 1-hydroxycanadine, N-methyl-ophiocarpine, 1,13-dihydroxy-N-methylcanadine, and 1-hydroxy-13-O-acetyl-N-methylcanadine.
128 . The engineered non-plant cell of claim 121 , wherein the benzylisoquinoline alkaloid product is a secoberberine product selected from the group consisting of: a narcotolinogendial, narcotolinal, 4′-O-desmethyl-3-O-acetylpapaveroxine, and 3-O-acetylpapaveroxine.
129 . The engineered non-plant cell of claim 121 , wherein the engineered non-plant cell is selected from the group consisting of microbial cells, insect cells, mammalian cells, bacterial cells, fungal cells, and yeast cells.
130 . The engineered non-plant cell of claim 121 , wherein the engineered non-plant cell is a reticuline-producing cell, comprising coding sequences for producing an enzyme selected from the group consisting of 6-pyruvoyl tetrahydrobiopterin synthase, sepiapterin reductase, 4a-hydroxytetrahydrobiopterin (pterin-4a-carbinolamine) dehydratase, quinonoid dihydropteridine reductase, dihydrofolate reductase, tyrosine hydroxylase, norcoclaurine synthase, L-DOPA decarboxylase, cytochrome P450 80B1, cytochrome P450 reductase, norcoclaurine 6-O-methyltransferase, 4′-O-methyltransferase, coclaurine-N-methyltransferase, 3-deoxy-d-arabinose-heptulosonate-7-phosphate synthase, chorismate mutase, phenylpyruvate decarboxylase, and transketalose, and wherein each coding sequence is chromosomally integrated into the reticuline-producing cell.
131 . A method for forming a product stream having a benzylisoquinoline alkaloid product that is downstream of canadine, the method comprising:
culturing an engineered non-plant cell that produces a benzylisoquinoline alkaloid product along a metabolic pathway that converts canadine to a noscapinoid product, wherein the noscapinoid product comprises at least one compound that is selected from the group consisting of: a narcotolinehemiacetal, narcotinehemiacetal, narcotoline, noscapine, 1-hydroxycanadine, N-methylcanadine, N-methyl-ophiocarpine, 1-hydroxy-N-methylcanadine, narcotolinal, 1,13-dihydroxy-N-methylcanadine, 1-hydroxy-13-O-acetyl-N-methylcanadine, 4′-O-desmethyl-3-O-acetylpapaveroxine, narcotolinogendial, and 3-O-acetylpapaveroxine, and wherein the engineered non-plant cell comprises at least one heterologous sequence encoding at least one enzyme involved in the metabolic pathway that converts canadine to a noscapinoid product; and
separating the benzylisoquinoline alkaloid product from cellular material to provide a product stream having the benzylisoquinoline alkaloid product.
132 . The method of claim 131 , wherein the at least one enzyme involved in the metabolic pathway that converts canadine to a noscapinoid product is selected from the group consisting of tetrahydroprotoberberine-N-methyltransferase, 1-hydroxy-N-methylcanadine 13-hydroxylase, N-methylcanadine 14-hydroxylase, 4′-O-desmethyl-3-O-acetylpapaveroxine synthase, 1,13-dihydroxy-N-methylcanadine 13-Oacetyltransferase, norcoclaurine 6-O-methyltransferase, narcotinehemiacetyl synthase, noscapine synthase, and narcotoline 4′-O-methylase I, and narcotoline 4′-O-methylase.
133 . The method of claim 131 , wherein the benzylisoquinoline alkaloid product is a phthalideisoquinoline product.
134 . The method of claim 131 , wherein the benzylisoquinoline alkaloid product is a secoberberine product.
135 . The method of claim 131 , wherein the engineered non-plant cell is a canadine-producing cell comprising coding sequences for producing an enzyme selected from the group consisting of 6-pyruvoyl tetrahydrobiopterin synthase, sepiapterin reductase, 4a-hydroxytetrahydrobiopterin (pterin-4a-carbinolamine) dehydratase, quinonoid dihydropteridine reductase, dihydrofolate reductase, tyrosine hydroxylase, norcoclaurine synthase, L-DOPA decarboxylase, cytochrome P450 80B1, cytochrome P450 reductase, norcoclaurine 6 methyltransferase, 4′-O-methyltransferase, coclaurine-N-methyltransferase, 3-deoxy-d-arabinose-heptulosonate-7-phosphate synthase, chorismate mutase, phenylpyruvate decarboxylase, transketalose, berberine bridge enzyme, scoulerine 9-O-methyltransferase, and canadine synthase, and wherein each coding sequence is chromosomally integrated into the canadine-producing cell.
136 . The method of claim 131 , wherein the engineered non-plant cell is selected from the group consisting of microbial cells, insect cells, mammalian cells, bacterial cells, fungal cells, and yeast cells.
137 . The method of claim 131 , wherein the product stream does not contain more than 5 ppm of a molecule selected from the group of lignin, flavonoids, phenanthreoids, latex, rubisco, meconic acid, pseudomorphine, narceine, thebaol, and pollen.
138 . The method of claim 131 , wherein the product stream contains at least one portion of a non-plant cell.
139 . The method of claim 138 , wherein the at least one portion of the non-plant cell is present in the product stream in a detectable amount which is detectable by a method selected from the group consisting of: liquid chromatography-mass spectrometry, mass spectrometry, and spectroscopy.
140 . The method of claim 131 , wherein the benzylisoquinoline alkaloid compound is produced within the engineered non-plant cell.